UNICOCELL BIOMED CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.7 TWD | +2.02% |
|
+9.31% | +3.25% |
| Mar. 07 | UnicoCell Biomed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 14.4M 441K | Sales 2023 | 24.59M 753K | Capitalization | 4.6B 141M |
|---|---|---|---|---|---|
| Net income 2022 | -91M -2.79M | Net income 2023 | -84M -2.57M | EV / Sales 2022 | 83.9 x |
| Net cash position 2022 | 147M 4.51M | Net cash position 2023 | 403M 12.35M | EV / Sales 2023 | 171 x |
| P/E ratio 2022 |
-14.5
x | P/E ratio 2023 |
-53.1
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.43% |
More Fundamentals
* Assessed data
| 1 day | +2.02% | ||
| 1 week | +9.31% | ||
| Current month | -0.12% | ||
| 1 month | -1.49% | ||
| 3 months | -2.50% | ||
| 6 months | +17.88% | ||
| Current year | +3.25% |
1 week
83.10
87.00
1 month
76.0089.00
Current year
76.0091.00
1 year
68.00104.00
3 years
31.00104.00
5 years
29.00104.00
10 years
29.00104.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chia Chu Tsai
CEO | Chief Executive Officer | - | 18-03-27 |
Pei Lin Chen
DFI | Director of Finance/CFO | - | 18-08-27 |
I Wen Tsai
CHM | Chairman | - | 18-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chia Fang Chang
BRD | Director/Board Member | - | 20-10-11 |
Ming Te Wang
BRD | Director/Board Member | - | 20-10-11 |
Su Lan Lin
BRD | Director/Board Member | - | 20-10-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 85.7 | +2.02% | 13 404 |
| 24-04-23 | 84 | -1.06% | 16,293 |
| 24-04-22 | 84.9 | -0.12% | 12,379 |
| 24-04-19 | 85 | -1.39% | 60,868 |
| 24-04-18 | 86.2 | +2.38% | 60,730 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
Unicocell Biomed Co Ltd is mainly engaged in the research and development of new adipose stem cell drugs and the application of stem cell technology. The main products include stem cell secretin and cell testing services. The Company's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.
| 1st Jan change | Capi. | |
|---|---|---|
| +3.25% | 144M | |
| -1.76% | 105B | |
| +3.33% | 97.5B | |
| +1.86% | 22.19B | |
| -16.61% | 21.33B | |
| -8.49% | 18.68B | |
| -42.33% | 16.6B | |
| -20.96% | 14.52B | |
| +5.02% | 14.09B | |
| +22.43% | 10.99B |
- Stock Market
- Equities
- 6794 Stock
